# Molecular Detection and Diagnostics Core

> **NIH NIH P20** · TULANE UNIVERSITY OF LOUISIANA · 2022 · $173,592

## Abstract

PROJECT SUMMARY/ABSTRACT (Molecular Detection and Diagnostics Core)
The Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases Phase 2 application
aims to further develop and strengthen the clinical and translational research infrastructure at Tulane University
and to continuously expand and support a critical mass of investigators with expertise in clinical and translational
research in cardiometabolic diseases. The newly proposed Molecular Detection and Diagnostics Core (MDDC)
will support the Research Project Leaders (RPLs), Pilot Project Leaders (PPLs), other COBRE investigators and
collaborators at Tulane University by providing cutting-edge instruments, innovative technologies and
methodologies, and expertise in multidisciplinary research including biochemistry, biomedical engineering,
analytical chemistry, proteomics, nanotechnology, and mass spectrometry (MS) to advance their clinical and
translational research in the etiology, prevention, diagnosis, and treatment of cardiometabolic disease. The
MDDC will develop and adapt integrated nanotechnology-based strategies and other innovative technologies to
identify novel biomarkers for early disease detection, prognostic evaluation, and the real-time monitoring of
treatment responses as well as to understand the molecular mechanisms of cardiometabolic disease. The MDDC
seeks to catalyze research that spans the analytical chemistry-biology interface, empowering investigators to
identify and solve important interdisciplinary research questions in the clinical and translational sciences of
cardiometabolic disease. Based on our team's expertise, the MDDC will provide COBRE investigators with
training and services in state-of-the-art analytical technologies such as MS and microarray-based proteomics
and organ-on-a-chip, among others, for the analysis of complex proteomes of tissue and biofluid samples. The
MDDC will also identify appropriate existing analytical methods as well as adapt newly developed methods, often
not available in the form of mature technologies. The MDDC will be housed within the Tulane University Center
for Cellular and Molecular Diagnostics, which has been well established for infectious and chronic disease
research. During the COBRE Phase 2, the MDDC will provide cutting-edge instruments and methodological
support for RPLs of Projects 2 and 3 to conduct their individual research projects. In addition, the MDDC will
provide expert consultation and state-of-the-art technologies for RPLs of Projects 1 and 4 to develop R01
applications to further investigate molecular mechanism of APOL1 on chronic kidney disease progression and
potassium intake on blood pressure reduction. The proposed MDDC will enhance the interactions and
collaborations among COBRE, non-COBRE and external investigators involved in molecular studies of
cardiometabolic disease. Since the MDDC is a critical component of the COBRE program, our long-term goal is
to grow MDDC into a sustaina...

## Key facts

- **NIH application ID:** 10504812
- **Project number:** 2P20GM109036-06A1
- **Recipient organization:** TULANE UNIVERSITY OF LOUISIANA
- **Principal Investigator:** Tony Y. Hu
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $173,592
- **Award type:** 2
- **Project period:** 2016-03-10 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10504812

## Citation

> US National Institutes of Health, RePORTER application 10504812, Molecular Detection and Diagnostics Core (2P20GM109036-06A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10504812. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*